FDA-cleared profile

Xeleris V Processing and Review Systems

GE Healthcare · PET/SPECT/Nuclear Medicine · FDA-cleared (510(k))

Authorized purpose: Xeleris V is intended for nuclear-medicine or radiology practitioners and referring physicians to display, process, archive, print, report, and network nuclear-medicine data from gamma cameras or PET scanners. PET or nuclear-medicine data may be registered or fused with CT or MR and physiologic signals to depict, localize, or quantify radionuclide tracers and anatomical structures. The labeled applications include DaTQUANT review of 123I-ioflupane images, Q.Lung support for pulmonary embolism, COPD, emphysema, lung-function assessment, and resection planning, and Q.Brain review of brain metabolic function or blood flow in specified neurologic conditions.

Clinical role
Nuclear-medicine image acquisition support, reconstruction, display, quantification, analysis, or comparison under professional review.
Images and patients
PET/SPECT/Nuclear Medicine · Whole-body, lung, brain/striatum, and other anatomy represented in nuclear-medicine, PET, CT, and MR studies
Key limitation
Keep in mind: Radiopharmaceutical, scan, reconstruction, quantitative, anatomy, and patient limits are exact-configuration dependent; clinical decisions remain with qualified clinicians.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Xeleris V is intended for nuclear-medicine or radiology practitioners and referring physicians to display, process, archive, print, report, and network nuclear-medicine data from gamma cameras or PET scanners. PET or nuclear-medicine data may be registered or fused with CT or MR and physiologic signals to depict, localize, or quantify radionuclide tracers and anatomical structures. The labeled applications include DaTQUANT review of 123I-ioflupane images, Q.Lung support for pulmonary embolism, COPD, emphysema, lung-function assessment, and resection planning, and Q.Brain review of brain metabolic function or blood flow in specified neurologic conditions.
  • Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Whole-body, lung, brain/striatum, and other anatomy represented in nuclear-medicine, PET, CT, and MR studies Input: Supported PET, SPECT, nuclear-medicine, CT, MR, tracer, physiologic-signal, and study inputs described in the labeling.
  • Who uses it?Intended users: Qualified radiologists, nuclear-medicine physicians, and trained imaging professionals.
  • What does the software produce?Output: Processed, fused, quantitative, comparative, and report-ready molecular-imaging views for professional review.
  • What is its most important limitation?Key limitation: Radiopharmaceutical, scan, reconstruction, quantitative, anatomy, and patient limits are exact-configuration dependent; clinical decisions remain with qualified clinicians.

Clinical takeaway. Clinical role: Xeleris V is intended for nuclear-medicine or radiology practitioners and referring physicians to display, process, archive, print, report, and network nuclear-medicine data from gamma cameras or PET scanners. PET or nuclear-medicine data may be registered or fused with CT or MR and physiologic signals to depict, localize, or quantify radionuclide tracers and anatomical structures. The labeled applications include DaTQUANT review of 123I-ioflupane images, Q.Lung support for pulmonary embolism, COPD, emphysema, lung-function assessment, and resection planning, and Q.Brain review of brain metabolic function or blood flow in specified neurologic conditions.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports design control testing with verified compliance to NEMA PS3.1 - 3.20 and IEC62304, plus additional engineering and clinical performance testing. It states Xeleris V did not require clinical studies; the deep-learning kidney and lung fissure segmentation algorithms were tested on representative clinical exams manually segmented by experienced NM Physicists and Physicians as ground truth, who scored the results on a 5-point Likert scale. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Xeleris V is intended for nuclear-medicine or radiology practitioners and referring physicians to display, process, archive, print, report, and network nuclear-medicine data from gamma cameras or PET scanners. PET or nuclear-medicine data may be registered or fused with CT or MR and physiologic signals to depict, localize, or quantify radionuclide tracers and anatomical structures. The labeled applications include DaTQUANT review of 123I-ioflupane images, Q.Lung support for pulmonary embolism, COPD, emphysema, lung-function assessment, and resection planning, and Q.Brain review of brain metabolic function or blood flow in specified neurologic conditions.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Nuclear-medicine image acquisition support, reconstruction, display, quantification, analysis, or comparison under professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported PET, SPECT, nuclear-medicine, CT, MR, tracer, physiologic-signal, and study inputs described in the labeling.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Processed, fused, quantitative, comparative, and report-ready molecular-imaging views for professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Clinical molecular-imaging and radiology environments within the labeled workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified radiologists, nuclear-medicine physicians, and trained imaging professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Radiopharmaceutical, scan, reconstruction, quantitative, anatomy, and patient limits are exact-configuration dependent; clinical decisions remain with qualified clinicians.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports design control testing with verified compliance to NEMA PS3.1 - 3.20 and IEC62304, plus additional engineering and clinical performance testing. It states Xeleris V did not require clinical studies; the deep-learning kidney and lung fissure segmentation algorithms were tested on representative clinical exams manually segmented by experienced NM Physicists and Physicians as ground truth, who scored the results on a 5-point Likert scale. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Xeleris V and its clinical applications successfully completed all design control testing per GE Healthcare’s quality system and also verified compliance with the relevant standards (i.e. NEMA PS3.1 - 3.20, IEC62304)." … "additional engineering and clinical performance testing was performed to provide the requisite data to demonstrate performance and substantiate claims.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports design control testing with verified compliance to NEMA PS3.1 - 3.20 and IEC62304, plus additional engineering and clinical performance testing. It states Xeleris V did not require clinical studies; the deep-learning kidney and lung fissure segmentation algorithms were tested on representative clinical exams manually segmented by experienced NM Physicists and Physicians as ground truth, who scored the results on a 5-point Likert scale. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Xeleris V and its clinical applications successfully completed all design control testing per GE Healthcare’s quality system and also verified compliance with the relevant standards (i.e. NEMA PS3.1 - 3.20, IEC62304)." … "additional engineering and clinical performance testing was performed to provide the requisite data to demonstrate performance and substantiate claims.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K201103 FDA decision evidence package for Xeleris V Processing and Review Systems

  • DesignFDA decision evidence and product verification described in the exact submission or PMA decision record.
  • PopulationWhole-body, lung, brain/striatum, and other anatomy represented in nuclear-medicine, PET, CT, and MR studies
  • Scopeexact submission
  • Tested versionXeleris V Processing and Review Systems configuration described in K201103
  • IndependenceSponsor or vendor study

K201103

FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation unless the exact source expressly establishes that distinction; local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K201103 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported PET, SPECT, nuclear-medicine, CT, MR, tracer, physiologic-signal, and study inputs described in the labeling.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K201103: Xeleris V Processing and Review Systems

  2. Routing

    Source context, not route validation: The exact FDA package describes nuclear-medicine and PET data with registered or fused CT or MR and physiologic signals, plus networking and reporting functions; verify local interfaces, identity, routing, and archive behavior.

    Scope: Exact FDA submission. This is a partial interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K201103: Xeleris V Processing and Review Systems

  3. AI processing

    Source context, not route validation: The exact FDA package describes Xeleris V running on a dedicated workstation or in a server-client configuration, with an option for the customer to have the software installed on a remote server. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "The system can run on dedicated workstation or in a server-client configuration." … "With Xeleris V, the customer now has an option where they can purchase the Xeleris V software, and have it installed on a remote server.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) decision material K201103: Xeleris V Processing and Review Systems

  4. Returned objects

    Source context, not route validation: Processed, fused, quantitative, comparative, and report-ready molecular-imaging views for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K201103: Xeleris V Processing and Review Systems

  5. Viewer/worklist/report

    Unresolved route: Processed, fused, quantitative, comparative, and report-ready molecular-imaging views for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K201103: Xeleris V Processing and Review Systems

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes Xeleris V running on a dedicated workstation or in a server-client configuration, with an option for the customer to have the software installed on a remote server. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The system can run on dedicated workstation or in a server-client configuration." … "With Xeleris V, the customer now has an option where they can purchase the Xeleris V software, and have it installed on a remote server.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact FDA package describes nuclear-medicine and PET data with registered or fused CT or MR and physiologic signals, plus networking and reporting functions; verify local interfaces, identity, routing, and archive behavior.
  • Exact FDA submission
  • Checked 2026-09-04

This is a partial interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

Training
Only qualified radiologists, nuclear-medicine physicians, and trained imaging professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K201103 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Radiopharmaceutical, scan, reconstruction, quantitative, anatomy, and patient limits are exact-configuration dependent; clinical decisions remain with qualified clinicians.
  • Exact FDA submission
  • Checked 2026-09-04

This is buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K201103 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared or authorized release includes them.

Deployment boundary

The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.

exact submission · checked 2026-09-04

FDA-described topology does not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The exact FDA package describes nuclear-medicine and PET data with registered or fused CT or MR and physiologic signals, plus networking and reporting functions; verify local interfaces, identity, routing, and archive behavior.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Radiopharmaceutical, scan, reconstruction, quantitative, anatomy, and patient limits are exact-configuration dependent; clinical decisions remain with qualified clinicians.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

exact submission · checked 2026-09-04

No exact-product price or reimbursement determination was promoted.

Lifecycle monitoring

Monitor K201103 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Radiopharmaceutical, scan, reconstruction, quantitative, anatomy, and patient limits are exact-configuration dependent; clinical decisions remain with qualified clinicians.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K201103
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
PET/SPECT/Nuclear Medicine
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Whole-body, lung, brain/striatum, and other anatomy represented in nuclear-medicine, PET, CT, and MR studies
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2020-09-25
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-19Last searched
27Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No exact-product reimbursement determination was promoted in this timeboxed review. Verify payer, site-of-service, coding, coverage, and local payment assumptions independently.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

5 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K201103: Xeleris V Processing and Review Systems

    U.S. Food and Drug Administration - Published 2020-09-25 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K201103 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251528

syngo.via MI Workflows; Scenium; syngo MBF

Siemens Medical Solutions USA, Inc.

Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF provide PET, SPECT, nuclear-medicine, CT, and MR viewing, manipulation, quantification, longitudinal comparison, and analysis for oncology, cardiology, neurology, organ function, and selected radiation-planning support.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2025-07-03
FDA-cleared K251153

Aurora

GE Medical Systems Israel

Authorized purpose: Aurora is a SPECT/CT system for nuclear-medicine uptake imaging, standalone CT, anatomical localization, attenuation correction, diagnosis, staging, therapy planning, guidance, and monitoring. K251153 adds deep-learning kidney segmentation to dynamic renal scintigraphy.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2025-06-12
FDA-cleared K243863

Opulus™ Lymphoma Precision

Roche Molecular Systems, Inc.

Authorized purpose: Opulus Lymphoma Precision segments and visualizes lesions and measures total metabolic tumor volume in whole-body FDG-PET/CT for patients already diagnosed with FDG-avid lymphoma; trained physicians can accept/reject annotated output, but radiologist review makes the final interpretation and the device is not a screening/diagnostic substitute.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole-body FDG-PET/CT
Decision
2025-05-30
FDA-cleared K233998

TRAQinform IQ

AIQ Global, Inc.

Authorized purpose: Quantitative single-timepoint or longitudinal analysis of lesion ROIs on adult PET/CT, including volume, density, and tracer-uptake changes, with a report used as an adjunct to local image interpretation.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body and lesion regions of interest
Decision
2024-09-05

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history